| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22004 |
| Drug | Amivantamab |
| Brand | Rybrevant® |
| Indication | For the treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum-based therapy. |
| Assessment Process | |
| Rapid review commissioned | 17/01/2022 |
| Rapid review completed | 03/02/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 23/02/2022 |
| Pre-submission consultation with Applicant | 28/03/2022 |
| Full submission received from Applicant | 30/08/2022 |
| Preliminary review sent to Applicant | 24/01/2023 |
| NCPE assessment re-commenced | 22/02/2023 |
| Factual accuracy sent to Applicant | 30/03/2023 |
| NCPE assessment re-commenced | 11/04/2023 |
| NCPE assessment completed | 28/04/2023 |
| NCPE assessment outcome | The NCPE recommends that amivantamab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
* This recommendation should be considered while also having regard to the criteria
specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
